Persistent insomnia is associated with mortality risk

Sairam Parthasarathy, Monica M. Vasquez, Marilyn Halonen, Richard R Bootzin, Stuart F Quan, Fernando Martinez, Stefano Guerra

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Background Insomnia has been associated with mortality risk, but whether this association is different in subjects with persistent vs intermittent insomnia is unclear. Additionally, the role of systemic inflammation in such an association is unknown. Methods We used data from a community-based cohort to determine whether persistent or intermittent insomnia, defined based on persistence of symptoms over a 6-year period, was associated with death during the following 20 years of follow-up. We also determined whether changes in serum C-reactive protein (CRP) levels measured over 2 decades between study initiation and insomnia determination were different for the persistent, intermittent, and never insomnia groups. The results were adjusted for confounders such as age, sex, body mass index, smoking, physical activity, alcohol, and sedatives. Results Of the 1409 adult participants, 249 (18%) had intermittent and 128 (9%) had persistent insomnia. During a 20-year follow-up period, 318 participants died (118 due to cardiopulmonary disease). In adjusted Cox proportional-hazards models, participants with persistent insomnia (adjusted hazards ratio [HR] 1.58; 95% confidence interval [CI], 1.02-2.45) but not intermittent insomnia (HR 1.22; 95% CI, 0.86-1.74) were more likely to die than participants without insomnia. Serum CRP levels were higher and increased at a steeper rate in subjects with persistent insomnia as compared with intermittent (P =.04) or never (P =.004) insomnia. Although CRP levels were themselves associated with increased mortality (adjusted HR 1.36; 95% CI, 1.01-1.82; P =.04), adjustment for CRP levels did not notably change the association between persistent insomnia and mortality. Conclusions In a population-based cohort, persistent, and not intermittent, insomnia was associated with increased risk for all-cause and cardiopulmonary mortality and was associated with a steeper increase in inflammation.

Original languageEnglish (US)
Pages (from-to)268-275.e2
JournalAmerican Journal of Medicine
Volume128
Issue number3
DOIs
StatePublished - Mar 1 2015

Fingerprint

Sleep Initiation and Maintenance Disorders
Mortality
C-Reactive Protein
Confidence Intervals
Blood Proteins
Inflammation
Hypnotics and Sedatives
Proportional Hazards Models
Body Mass Index
Smoking
Alcohols

Keywords

  • Cardiovascular
  • Chronic insomnia
  • Mortality
  • Sleep

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Persistent insomnia is associated with mortality risk. / Parthasarathy, Sairam; Vasquez, Monica M.; Halonen, Marilyn; Bootzin, Richard R; Quan, Stuart F; Martinez, Fernando; Guerra, Stefano.

In: American Journal of Medicine, Vol. 128, No. 3, 01.03.2015, p. 268-275.e2.

Research output: Contribution to journalArticle

Parthasarathy, Sairam ; Vasquez, Monica M. ; Halonen, Marilyn ; Bootzin, Richard R ; Quan, Stuart F ; Martinez, Fernando ; Guerra, Stefano. / Persistent insomnia is associated with mortality risk. In: American Journal of Medicine. 2015 ; Vol. 128, No. 3. pp. 268-275.e2.
@article{39b626190f4d46cdacbb98475571427d,
title = "Persistent insomnia is associated with mortality risk",
abstract = "Background Insomnia has been associated with mortality risk, but whether this association is different in subjects with persistent vs intermittent insomnia is unclear. Additionally, the role of systemic inflammation in such an association is unknown. Methods We used data from a community-based cohort to determine whether persistent or intermittent insomnia, defined based on persistence of symptoms over a 6-year period, was associated with death during the following 20 years of follow-up. We also determined whether changes in serum C-reactive protein (CRP) levels measured over 2 decades between study initiation and insomnia determination were different for the persistent, intermittent, and never insomnia groups. The results were adjusted for confounders such as age, sex, body mass index, smoking, physical activity, alcohol, and sedatives. Results Of the 1409 adult participants, 249 (18{\%}) had intermittent and 128 (9{\%}) had persistent insomnia. During a 20-year follow-up period, 318 participants died (118 due to cardiopulmonary disease). In adjusted Cox proportional-hazards models, participants with persistent insomnia (adjusted hazards ratio [HR] 1.58; 95{\%} confidence interval [CI], 1.02-2.45) but not intermittent insomnia (HR 1.22; 95{\%} CI, 0.86-1.74) were more likely to die than participants without insomnia. Serum CRP levels were higher and increased at a steeper rate in subjects with persistent insomnia as compared with intermittent (P =.04) or never (P =.004) insomnia. Although CRP levels were themselves associated with increased mortality (adjusted HR 1.36; 95{\%} CI, 1.01-1.82; P =.04), adjustment for CRP levels did not notably change the association between persistent insomnia and mortality. Conclusions In a population-based cohort, persistent, and not intermittent, insomnia was associated with increased risk for all-cause and cardiopulmonary mortality and was associated with a steeper increase in inflammation.",
keywords = "Cardiovascular, Chronic insomnia, Mortality, Sleep",
author = "Sairam Parthasarathy and Vasquez, {Monica M.} and Marilyn Halonen and Bootzin, {Richard R} and Quan, {Stuart F} and Fernando Martinez and Stefano Guerra",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.amjmed.2014.10.015",
language = "English (US)",
volume = "128",
pages = "268--275.e2",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Persistent insomnia is associated with mortality risk

AU - Parthasarathy, Sairam

AU - Vasquez, Monica M.

AU - Halonen, Marilyn

AU - Bootzin, Richard R

AU - Quan, Stuart F

AU - Martinez, Fernando

AU - Guerra, Stefano

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Background Insomnia has been associated with mortality risk, but whether this association is different in subjects with persistent vs intermittent insomnia is unclear. Additionally, the role of systemic inflammation in such an association is unknown. Methods We used data from a community-based cohort to determine whether persistent or intermittent insomnia, defined based on persistence of symptoms over a 6-year period, was associated with death during the following 20 years of follow-up. We also determined whether changes in serum C-reactive protein (CRP) levels measured over 2 decades between study initiation and insomnia determination were different for the persistent, intermittent, and never insomnia groups. The results were adjusted for confounders such as age, sex, body mass index, smoking, physical activity, alcohol, and sedatives. Results Of the 1409 adult participants, 249 (18%) had intermittent and 128 (9%) had persistent insomnia. During a 20-year follow-up period, 318 participants died (118 due to cardiopulmonary disease). In adjusted Cox proportional-hazards models, participants with persistent insomnia (adjusted hazards ratio [HR] 1.58; 95% confidence interval [CI], 1.02-2.45) but not intermittent insomnia (HR 1.22; 95% CI, 0.86-1.74) were more likely to die than participants without insomnia. Serum CRP levels were higher and increased at a steeper rate in subjects with persistent insomnia as compared with intermittent (P =.04) or never (P =.004) insomnia. Although CRP levels were themselves associated with increased mortality (adjusted HR 1.36; 95% CI, 1.01-1.82; P =.04), adjustment for CRP levels did not notably change the association between persistent insomnia and mortality. Conclusions In a population-based cohort, persistent, and not intermittent, insomnia was associated with increased risk for all-cause and cardiopulmonary mortality and was associated with a steeper increase in inflammation.

AB - Background Insomnia has been associated with mortality risk, but whether this association is different in subjects with persistent vs intermittent insomnia is unclear. Additionally, the role of systemic inflammation in such an association is unknown. Methods We used data from a community-based cohort to determine whether persistent or intermittent insomnia, defined based on persistence of symptoms over a 6-year period, was associated with death during the following 20 years of follow-up. We also determined whether changes in serum C-reactive protein (CRP) levels measured over 2 decades between study initiation and insomnia determination were different for the persistent, intermittent, and never insomnia groups. The results were adjusted for confounders such as age, sex, body mass index, smoking, physical activity, alcohol, and sedatives. Results Of the 1409 adult participants, 249 (18%) had intermittent and 128 (9%) had persistent insomnia. During a 20-year follow-up period, 318 participants died (118 due to cardiopulmonary disease). In adjusted Cox proportional-hazards models, participants with persistent insomnia (adjusted hazards ratio [HR] 1.58; 95% confidence interval [CI], 1.02-2.45) but not intermittent insomnia (HR 1.22; 95% CI, 0.86-1.74) were more likely to die than participants without insomnia. Serum CRP levels were higher and increased at a steeper rate in subjects with persistent insomnia as compared with intermittent (P =.04) or never (P =.004) insomnia. Although CRP levels were themselves associated with increased mortality (adjusted HR 1.36; 95% CI, 1.01-1.82; P =.04), adjustment for CRP levels did not notably change the association between persistent insomnia and mortality. Conclusions In a population-based cohort, persistent, and not intermittent, insomnia was associated with increased risk for all-cause and cardiopulmonary mortality and was associated with a steeper increase in inflammation.

KW - Cardiovascular

KW - Chronic insomnia

KW - Mortality

KW - Sleep

UR - http://www.scopus.com/inward/record.url?scp=84924208308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924208308&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2014.10.015

DO - 10.1016/j.amjmed.2014.10.015

M3 - Article

C2 - 25447616

AN - SCOPUS:84924208308

VL - 128

SP - 268-275.e2

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 3

ER -